The Food and Drugs Authority has for the first time approved a herbal medicine known as Cryptolepsis Sanguinolenta which is locally known as Niniba for clinical trials in January, 2021.
According to a press statement issued by FDA, the medicine was developed by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology, Kumasi and was submitted for assessment of safety and efficacy as potential treatment for COVID-19 in September, 2020. This, the statement says came after a laboratory studies was conducted.
“The FDA after a detailed assessment of the application gave the requisite regulatory authorisation for the conduct of the trial as per the mandate outlined under part II (Section150-166) of the Public Health Act 2012(Act 851) which gives the Authority the legal mandate to regulate clinical trials of drugs, herbal medicine products, cosmetics or medical devices” , it states.
It also said the trial will be conducted in two sites, however the sites were not communicated.
Below is a copy of the press statement:
Source: Opemsuo.com/Hajara Fuseini